Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Peter Lin MD, CCFP

Peter Lin MD, CCFP

Director, Primary Care Initiatives, Canadian Heart Research Centre, North York, Ontario

Dr. Peter Lin, a primary care physician, is the Director of Primary Care Initiatives at the Canadian Heart Research Centre and has two busy family medicine practices in Toronto. For 7 years, he served as the medical director at the University of Toronto Scarborough Health & Wellness Centre. In 2011, he received a teaching award from the College of Family Physicians of Canada.

Dr. Lin has worked with KDIGO (Kidney Disease│Improving Global Outcomes) in an effort to help enhance care for patients with chronic kidney disease. He has been a contributing author to the Canadian Diabetes Guidelines and has served on the editorial board of Pri-Med Institute, which provides education for physicians.

Dr. Lin maintains an active lecture schedule, reflecting his varied medical interests, continuing his focus on bridging the chasm between research and clinical practice.

Disclosures

  • Consultant (continuing medical education programs): AstraZeneca; Boehringer Ingelheim; Bayer; Eli Lilly; Amgen; Janssen; Merck; Pfizer; Sanofi; Abbott; HLS Therapeutics

Recent Contributions to PracticeUpdate:

  1. Prevalence and Predictors of Primary Nonadherence to Medications Prescribed in Primary Care
  2. Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas in Reducing the Risk of Major Adverse Cardiovascular Events
  3. Dupilumab for Patients With COPD With Type 2 Inflammation Indicated by Eosinophil Counts
  4. Association of Exposure to Extreme Temperature Events and Fine Particulate Matter With Myocardial Infarction–Related Mortality
  5. Association Between Serum 25-Hydroxyvitamin D Levels and the Risk of Colorectal Cancer
  6. Protective Effect of HDL-C Against Cardiovascular Disease
  7. Safety and Effectiveness of Self-Administered Intranasal Etripamil for Atrioventricular Nodal–Dependent Supraventricular Tachycardia
  8. Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers
  9. Association of Statin Initiation With the Risk of Incident Kidney Disease in Patients With Diabetes
  10. Sulfonylureas as Second-Line Drugs for Cardiovascular Safety in Type 2 Diabetes

Most Read This Week

Recently Updated